Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Receives “Complete Response” Letter For Cimzia

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm says FDA seeks new information and clarification regarding the BLA.
Advertisement

Related Content

UCB Wins FDA Nod For Cimzia In Crohn’s
EU Committee Upholds Negative Opinions On Cimzia, Rhucin Applications
UCB’s Cimzia Shows Strong Interim Results In Phase IIIb For Crohn’s Disease
UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis
UCB’s Cimzia Rejected For Crohn’s By EMEA Committee
UCB’s Cimzia Could Be Delayed Until 2008 Or Later For Crohn’s
UCB Licenses BioWa Antibody Technology
J&J Suspends Enrollment In Golimumab Trials Due To Distribution Issue
UCB Cimzia BLA Submission Could Provide First Subcutaneous Injection For Crohn’s
UCB Cimzia BLA Submission Could Provide First Subcutaneous Injection For Crohn’s

Topics

Advertisement
UsernamePublicRestriction

Register

PS063596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel